Alpha -1 Antitrypsin

Phase 2Small molecule

KKamada, Ltd.

Alpha -1 Antitrypsin is one of 70 small molecule programs targeting Bronchiolitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BronchiolitisActive, not recruiting

Acute Myocardial InfarctionActive, not recruiting

BronchiolitisPhase 2

Active, not recruiting

Acute Myocardial InfarctionPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

216 competitors in Acute Myocardial Infarction

#DrugCompanyPhaseTrials

Adenocard

Astellas

Phase 3

2 2

Lovenox

Sanofi

Phase 3

2 3

Byetta

AstraZeneca

Phase 3

1 4

Kineret

SSwedish Orphan Biovitrum

Phase 3

2 5

Glucophage

EMD Serono

Phase 3

1 6

Neupogen

EEastern Cooperative Oncology Group

Phase 3

1 7

Jardiance

Boehringer Ingelheim

Phase 3

1 8

Xarelto

WWim Janssens

Phase 3

1 9

Rayaldee

OOrganon and Co

Phase 3

1 10

Cyclosporine a

Novartis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2031

Phase 3Recruiting

Efficacy and Safety

NCT04204252

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes

Completed·KKamada, Ltd.·Phase 2·NCT02005848·70 enrolled

Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"

Recruiting·KKamada, Ltd.·Phase 3·NCT04204252·220 enrolled

Bronchiolitis1 trial

Safety and Efficacy of Inhaled Alpha-1 Antitrypsin in Preventing Bronchiolitis Obliterable Syndrome in Lung Transplant Recipients

Unknown status·RRabin Medical Center·Phase 2·NCT01394835·40 enrolled

Acute Myocardial Infarction1 trial

Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction

Completed·VVirginia Commonwealth University·Phase 1/2·NCT01936896·10 enrolled

Refractory1 trial

A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD

Completed·JJohn Levine·Phase 2·NCT03459040·30 enrolled

SLE1 trial

Aralast NP in Islet Transplant

Completed·UUniversity of Alberta·Phase 1/2·NCT02520076·5 enrolled

3 more indications

Anti-inflammatory Therapy1 trial

Anti-inflammatory Therapy to Improve Outcomes After TPIAT

Completed·UUniversity of Minnesota·Phase 4·NCT02713997·43 enrolled

Renal Transplant1 trial

Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant

Completed·MMassachusetts General Hospital·Phase 2·NCT02464878·2 enrolled

Injury1 trial

Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery

Unknown status·SSoroka University Medical Center·Phase 1/2·NCT02191839·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Alpha -1 Antitrypsin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Alpha -1 Antitrypsin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Alpha -1 Antitrypsin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kamada, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: KKamada, Ltd.

Alpha -1 Antitrypsin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2031

Trials by Indication[1]

Efficacy and Safety2 trials

Bronchiolitis1 trial

Acute Myocardial Infarction1 trial

Refractory1 trial

SLE1 trial

Anti-inflammatory Therapy1 trial

Renal Transplant1 trial

Injury1 trial

References

Drug Info

Quick Facts

Related News